Boston Trust Walden’s Vertex Pharmaceuticals VRTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$230K Sell
439
-46
-9% -$23.6K ﹤0.01% 383
2026
Q2
$241K Hold
485
– – ﹤0.01% 383
2026
Q1
$217K Hold
485
– – ﹤0.01% 384
2025
Q4
$220K Buy
+485
New +$209K ﹤0.01% 375
2025
Q3
– Sell
-485
Closed -$216K – 403
2025
Q2
$216K Sell
485
-125
-20% -$57.6K ﹤0.01% 368
2025
Q1
$296K Sell
610
-200
-25% -$93.2K ﹤0.01% 348
2024
Q4
$326K Sell
810
-150
-16% -$69.5K ﹤0.01% 342
2024
Q3
$446K Sell
960
-150
-14% -$72.1K ﹤0.01% 324
2024
Q2
$520K Hold
1,110
– – ﹤0.01% 316
2024
Q1
$464K Hold
1,110
– – ﹤0.01% 323
2023
Q4
$452K Hold
1,110
– – ﹤0.01% 318
2023
Q3
$386K Hold
1,110
– – ﹤0.01% 318
2023
Q2
$391K Hold
1,110
– – ﹤0.01% 320
2023
Q1
$350K Hold
1,110
– – ﹤0.01% 328
2022
Q4
$321K Hold
1,110
– – ﹤0.01% 335
2022
Q3
$321K Hold
1,110
– – ﹤0.01% 325
2022
Q2
$313K Sell
1,110
-90
-8% -$24.1K ﹤0.01% 331
2022
Q1
$313K Hold
1,200
– – ﹤0.01% 344
2021
Q4
$264K Sell
1,200
-33
-3% -$6.42K ﹤0.01% 368
2021
Q3
$224K Buy
1,233
+33
+3% +$6.44K ﹤0.01% 376
2021
Q2
$242K Hold
1,200
– – ﹤0.01% 369
2021
Q1
$258K Hold
1,200
– – ﹤0.01% 352
2020
Q4
$284K Sell
1,200
-308
-20% -$70.7K ﹤0.01% 348
2020
Q3
$410K Hold
1,508
– – 0.01% 322
2020
Q2
$438K Hold
1,508
– – 0.01% 318
2020
Q1
$359K Hold
1,508
– – 0.01% 320
2019
Q4
$330K Hold
1,508
– – ﹤0.01% 349
2019
Q3
$255K Hold
1,508
– – ﹤0.01% 359
2019
Q2
$277K Hold
1,508
– – ﹤0.01% 356
2019
Q1
$277K Hold
1,508
– – ﹤0.01% 359
2018
Q4
$250K Hold
1,508
– – ﹤0.01% 358
2018
Q3
$291K Sell
1,508
-50
-3% -$8.9K ﹤0.01% 357
2018
Q2
$265K Hold
1,558
– – ﹤0.01% 363
2018
Q1
$254K Sell
1,558
-625
-29% -$102K ﹤0.01% 368
2017
Q4
$327K Hold
2,183
– – ﹤0.01% 353
2017
Q3
$332K Sell
2,183
-125
-5% -$18.8K 0.01% 352
2017
Q2
$297K Buy
+2,308
New +$278K ﹤0.01% 355

Other funds holding VRTX

Boston Trust Walden's VRTX Position: Q3 2026 in Review

Boston Trust Walden reduced its Vertex Pharmaceuticals (VRTX) stake by 9.5% in Q3 2026, selling an estimated $23.6K and leaving 439 shares worth $230K. The position accounts for ﹤0.01% of the portfolio, ranked #383.

Boston Trust Walden first reported a position in VRTX in Q2 2017 and has held it in 37 quarters since. The position peaked at $520K in Q2 2024. 1,161 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

  • Boston Trust Walden held 439 shares of Vertex Pharmaceuticals worth $230K as of Q3 2026.
  • Boston Trust Walden sold 46 Vertex Pharmaceuticals shares in Q3 2026, an estimated $23.6K.
  • Vertex Pharmaceuticals made up ﹤0.01% of Boston Trust Walden's portfolio in Q3 2026, its #383 holding.
  • Boston Trust Walden first reported a position in Vertex Pharmaceuticals in Q2 2017 and has held it in 37 quarters since.
  • Boston Trust Walden's Vertex Pharmaceuticals position peaked at $520K in Q2 2024.
  • 1,161 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Boston Trust Walden's 13F filing for Q3 2026, filed 30 Oct 2026.